ClinicalTrials.gg
RecruitingNCT07658183Updated Oct 21, 2026

A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

A Phase 2 interventional study of BL0175 Injection and BL0175 Injection in Breast Cancer (Locally Advanced or Metastatic), sponsored by Shanghai Best-Link Bioscience, LLC. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Shanghai Best-Link Bioscience, LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 21, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
756th of 1,519
120 · median 120
Started
2026
with 184 others
Phase 2
493 of 1,928
243 open now
Primary completion
2027-10
later than 736 of 1,063 live
Registered
1,842nd of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 756th largest by planned enrollment of the 1,519 interventional ones that give a count, is one of 185 that started in 2026, is one of 493 in phase 2, reaches primary completion later than 736 of the 1,063 other live ones, and was the 1,842nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

860 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the objective response rates (ORR) of different doses of BL0175 in patients with postmenopausal hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The main questions it aims to answer are:

  1. Which dose level of BL0175 demonstrates the optimal ORR?
  2. What is the recommended phase 3 dose (RP3D) based on efficacy and safety data across the tested dose levels?
03

Conditions studied

  • Breast Cancer (Locally Advanced or Metastatic)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in the trial, understanding the specific procedures of the trial, and willing to sign a written form.
  2. Age ≥ 18 years.
  3. HR positive, negative, with locally advanced or breast cancer in patients during or after endocrine therapy.
  4. The blood pregnancy test result during the screening period must be negative (if the postmenopausal state is caused by GnRH agonists).
  5. If the postmenopausal state is caused by GnRH agonists, the trial participants must agree to take effective measures from the time of enrollment until at least 2 years after the last administration of the study treatment. For patients with breast cancer, the use of estrogen-based hormonal contraceptive methods (including hormone-type intrauterine devices) is not allowed, while the efficacy of progestin-based hormonal contraceptive methods is currently unclear. Effective contraceptive measures include: a. Complete abstinence (if it is their preferred regular lifestyle); b. Intrauterine device; c. Bilateral tubal ligation; d. The partner has undergone vasectomy and confirmed no sperm; e. Dual barrier method (male condom combined with cervical cap, vaginal diaphragm, or contraceptive sponge in combination with spermicidal agent).
  6. At least one exists.
  7. The (ECOG) status score at screening must be ≤ 1.
  8. ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Participants with symptomatic central nervous system (CNS) or cancerous meningitis;
  2. Have a history of other primary malignant tumors (except for participants who have been cured of skin basal cell carcinoma, skin squamous cell carcinoma, or cervical carcinoma in situ, and participants with other primary tumors that have no evidence of disease for 2 years or more and do not require treatment).
  3. Patients whose pericardial effusion, pleural effusion or ascites remain uncontrollable after intervention.
  4. Participants who have a history of transplantation (including but not limited to allogeneic organ, bone marrow, or stem cell transplantation).
  5. A history of allergic to fulvestrant, or prone to allergic reactions (such as prone to angioedema, urticaria, asthma, rash, etc.).
  6. Severe cardiovascular or cerebrovascular diseases, including: Heart failure classified as (NYHA) functional class III-IV (assessment only for patients with a history of heart disease), or (LVEF) \<50% (if LVEF data are available); Uncontrolled ventricular arrhythmias: baseline corrected by Fridericia method (QTcF) > 480 ms, or congenital long QT syndrome; Myocardial infarction, severe or unstable angina, congestive heart failure, cerebrovascular accident (including ), symptomatic pulmonary embolism, or other thromboembolic events occurring within 6 months prior to the first administration of the drug, or coronary artery bypass graft surgery performed within 6 months prior to the first administration of the investigational drug; Clinically symptomatic bradycardia as assessed by the investigator; Other clinically significant cardiovascular diseases that, in the opinion of the investigator, make the patient unsuitable for participation in the trial.
  7. (HIV) infection or positive HIV antibody test at screening.
  8. Active (HBV DNA ≥2000 IU/mL) or active (HCV RNA ≥200 IU/mL). Additionally, eligible participants with hepatitis B or C must agree to receive antiviral treatment according to established guidelines; otherwise, they will not be enrolled.
  9. Active infection requiring intravenous antibiotic therapy within 1 week prior to the first administration of the investigational drug.
  10. Moderate or severe hepatic impairment, defined as meeting classification criteria B or C.
  11. Insufficient organ function reserve at baseline, as defined by any of the following criteria (no blood products [including or red blood cells] or colony-stimulating factors [including granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, or recombinant erythropoietin] administered within 7 days prior to testing): (ANC) \<1.5×10⁹/L; Total >1.5×; or AST >3×ULN if no liver metastasis is present; ALT or AST >5×ULN if liver metastasis is present; (Hb) \<90 g/L; Platelet count (PLT) \<100×10⁹/L; (INR) >1.5 (for patients on anticoagulant therapy, values within therapeutic range are acceptable); \<30 mL/min.
  12. Receipt of anti-tumor drugs or investigational agents within the following time intervals prior to the first administration of the investigational drug: Anti-tumor endocrine therapy, targeted small-molecule therapy, or radiotherapy (except palliative radiotherapy or radiotherapy not involving the planned target lesion) ≤14 days or 5 half-lives (whichever is shorter); Chemotherapy ≤28 days or 5 half-lives (whichever is shorter); Immunotherapy or cell therapy (e.g., chimeric antigen receptor T-cell therapy) ≤28 days; other forms of cell therapy must be discussed with the investigator to determine eligibility; Monoclonal antibodies used for anti-tumor treatment ≤28 days; Traditional Chinese medicine with a clearly defined anti-tumor indication ≤14 days; therapy for any reason ≤7 days; All other investigational drugs or devices ≤28 days or 5 half-lives (whichever is shorter).
  13. Bleeding disorders (e.g., disseminated intravascular coagulation, deficiency of coagulation factors), or requiring long-term anticoagulant therapy (excluding antiplatelet therapy and low-dose warfarin or low-molecular-weight heparin).
  14. Severe vascular embolic events requiring medical or surgical intervention.
  15. Active diseases requiring systemic treatment (including use of immunomodulatory agents, , or immunosuppressive drugs).

    Note: Patients with hyperthyroidism/hypothyroidism are eligible for enrollment. Hormonal replacement therapy and symptomatic treatments (e.g., levothyroxine for adrenal or pituitary insufficiency, insulin, or physiologic corticosteroid replacement) are not considered forms of systemic therapy and are permitted.

  16. Received systemic corticosteroids within 4 weeks prior to the first administration of the investigational medicinal product (except low-dose corticosteroids, such as ≤20 mg prednisone per day or equivalent).
  17. Underwent major surgery within 4 weeks prior to the first administration of the investigational medicinal product, or planned to undergo major surgery during the study period.
  18. Currently pregnant or breastfeeding, or expected to become pregnant during the study period (from screening visit through 2 years after the last dose of study treatment).
  19. Not recovered from toxicity related to prior treatment (including prior immunotherapy) and/or complications from surgical interventions to a v6.0 grade ≤1.

    Note: Participants with stable chronic adverse events (≤grade 2) that are not expected to resolve spontaneously (e.g., peripheral neuropathy and alopecia) are allowed.

  20. Any other condition deemed unsuitable for participation in this trial by the investigator.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    BL0175 250mg

    Group A

    Drug: BL0175 Injection

  • Experimental
    BL0175 500mg

    Group B

    Drug: BL0175 Injection

Interventions

  • Participants will receive BL0175 Injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), and thereafter on Day 1 of each subsequent 28-day treatment cycle (CnD1, n ≥ 2). Each treatment cycle is defined as 28 consecutive days. Each dose is 250 mg, administered as a unilateral gluteal intramuscular injection. Treatment will continue until disease progression, intolerable toxicity, withdrawal from the study, or study termination/end of study, whichever occurs first.

  • Participants will receive BL0175 Injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), and thereafter once on Day 1 of each subsequent 28-day treatment cycle (CnD1). Each treatment cycle is defined as 28 consecutive days. The total dose per administration is 500 mg, administered as bilateral gluteal intramuscular injections at 250 mg per buttock. Treatment will continue until disease progression, intolerable toxicity, withdrawal from the study, or study termination/end of study, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate Evaluated by Blinded Independent Central Review

    Time frame: 12 months

Secondary outcomes

  1. Progression Free Survival Evaluated by BICR

    Time frame: 12 months

  2. Clinical Benefit Rate Evaluated by BICR

    Time frame: 12 months

  3. Disease Control Rate Evaluated by BICR

    Time frame: 12 months

  4. Duration of Response Evaluated by BICR

    Time frame: 12 months

  5. Objective Response Rate Evaluated by the Investigator

    Time frame: 12 months

  6. Progression Free Survival Evaluated by the Investigator

    Time frame: 12 months

  7. Clinical Benefit Rate Evaluated by the Investigator

    Time frame: 12 months

  8. Disease Control Rate Evaluated by the Investigator

    Time frame: 12 months

  9. Duration of Response Evaluated by the Investigator

    Time frame: 12 months

  10. Overall Survival Rate

    Time frame: 12 months

  11. Adverse Event

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2027, 13 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 13 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 18, 2026
StartActual
Sep 9, 2026was Jul 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
May 31, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
1 site added — first site in China
Show site
  • Fudan University Shanghai Cancer Center · Shanghai, China
Oct 21, 2026
Start date
Jul 20, 2026→Sep 9, 2026 (actual)
Oct 21, 2026
Interventions
Changed BL0175→BL0175 Injection. Added Drug: BL0175 Injection
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Fudan University Shanghai Cancer Center · Shanghai, China
    Start date Jul 20, 2026→Sep 9, 2026 (now actual)
    Interventions Changed BL0175→BL0175 Injection. Added Drug: BL0175 Injection
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07658183
Lead sponsor
Shanghai Best-Link Bioscience, LLC
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Sep 9, 2026
Primary completion
Oct 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Lun Zhuo Fang
Contact
syner2000@163.com
86+18357916536

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BL0175

Start the discussion